Major Depressive Disorder is an indication for drug development with over 130 pipeline drugs currently active. According to GlobalData, preregistered drugs for Major Depressive Disorder have a 76.92% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Major Depressive Disorder compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Major Depressive Disorder overview
Major Depressive Disorder (MDD) is a common and severe mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in daily activities. Symptoms may include changes in appetite and sleep patterns, fatigue, difficulty concentrating, feelings of worthlessness, and thoughts of death or suicide. Diagnosis is based on the duration and intensity of these symptoms. Various factors, including genetics, brain chemistry, and life events, contribute to MDD. Treatment often involves a combination of psychotherapy, medication (antidepressants), and lifestyle changes. Timely intervention and ongoing support are crucial for managing and overcoming Major Depressive Disorder.
For a complete picture of PTSR and LoA scores for drugs in Major Depressive Disorder, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
